To the full analysis
Faes Farma stock: growth
FAE.MCFaes Farma reported $676.46M in revenue for fiscal 2025, up 23.7% on the prior year, up 9.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.5%
per year from 2006 to 2025, per share 2.6%
Earnings (Annual rate)
6.8%
per year from 2006 to 2025, per share 2.9%
Free cash flow (Annual rate)
9.4%
per year from 2006 to 2025, per share 5.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.9% | 11.5% | 6.5% |
| Revenue per share | 7.6% | 9.2% | 2.6% |
| Earnings | 1.9% | 10.1% | 6.8% |
| Earnings per share | 0.0% | 8.0% | 2.9% |
| Free cash flow | 3.4% | 7.3% | 9.4% |
| Free cash flow per share | 1.2% | 5.1% | 5.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $205.21M | $25.23M | $12.53M |
| 2007 | $206.04M | $24.54M | $2.01M |
| 2008 | $215.17M | $21.74M | $20.05M |
| 2009 | $145.61M | $20.12M | $7.03M |
| 2010 | $224.4M | $22.16M | $5.73M |
| 2011 | $210.79M | $15.71M | $13.2M |
| 2012 | $195.15M | $21.63M | $23.4M |
| 2013 | $199.89M | $25.05M | $30.45M |
| 2014 | $212.47M | $28.07M | $31.15M |
| 2015 | $226.85M | $33.64M | $34.09M |
| 2016 | $253.35M | $40.55M | $41.71M |
| 2017 | $304.26M | $46.79M | $27.79M |
| 2018 | $359.37M | $57.17M | $51.71M |
| 2019 | $396.03M | $70.88M | $51.17M |
| 2020 | $421.34M | $80.39M | $58.47M |
| 2021 | $441.64M | $91.3M | $22.41M |
| 2022 | $486.18M | $99.17M | $28.63M |
| 2023 | $499.94M | $101.84M | −$1.35M |
| 2024 | $547.01M | $123.4M | $84.16M |
| 2025 | $676.46M | $88.24M | $69.13M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.